 Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKK
- MAPKKs
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
- MAPK Kinases
- Kinases, MAPK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 | | 1995 | 0 | 3 | 3 | | 1996 | 1 | 3 | 4 | | 1997 | 5 | 3 | 8 | | 1998 | 5 | 2 | 7 | | 1999 | 4 | 3 | 7 | | 2000 | 3 | 3 | 6 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 6 | 7 | | 2003 | 2 | 4 | 6 | | 2004 | 2 | 2 | 4 | | 2005 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 2 | 3 | | 2015 | 0 | 3 | 3 | | 2016 | 0 | 2 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga ?, Rudin CM, Somwar R, Ladanyi M. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. J Thorac Oncol. 2023 09; 18(9):1165-1183.
-
Sheppard SE, March ME, Seiler C, Matsuoka LS, Kim SE, Kao C, Rubin AI, Battig MR, Khalek N, Schindewolf E, O'Connor N, Pinto E, Priestley JR, Sanders VR, Niazi R, Ganguly A, Hou C, Slater D, Frieden IJ, Huynh T, Shieh JT, Krantz ID, Guerrero JC, Surrey LF, Biko DM, Laje P, Castelo-Soccio L, Nakano TA, Snyder K, Smith CL, Li D, Dori Y, Hakonarson H. Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition. JCI Insight. 2023 05 08; 8(9).
-
Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
-
Geddes GC, Parent JJ, Lander J, Jeewa A, Ware SM, Villa C, Chatfield KC, Weaver KN. MEK Inhibition Improves Cardiomyopathy in Costello Syndrome. J Am Coll Cardiol. 2023 04 11; 81(14):1439-1441.
-
Rush C, Sabus A, Bradley ZK, Herbert M, Hemenway M. The incidence and characterization of weight gain associated with MEK inhibitors in pediatric patients. Pediatr Blood Cancer. 2023 04; 70(4):e30182.
-
Bhatt V, Lan T, Wang W, Kong J, Lopes EC, Wang J, Khayati K, Raju A, Rangel M, Lopez E, Hu ZS, Luo X, Su X, Malhotra J, Hu W, Pine SR, White E, Guo JY. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors. Cell Death Dis. 2023 01 26; 14(1):61.
-
Hazegh K, Fang F, Kelly K, Sinchar D, Wang L, Zuchelkowski BE, Ufelle AC, Esparza O, Davizon-Castillo P, Page GP, Kanias T. Erythrocyte mitogen-activated protein kinases mediate hemolytic events under osmotic and oxidative stress and in hemolytic diseases. Cell Signal. 2022 11; 99:110450.
-
Parsegian K. The inhibition of mineralisation by fibroblast growth factor 2 is associated with the altered expression of genes regulating phosphate balance. Aust Endod J. 2023 Aug; 49(2):324-331.
-
Nakano TA, Rankin AW, Annam A, Kulungowski AM, McCallen LM, Hill LR, Chatfield KC. Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. J Pediatr. 2022 09; 248:81-88.e1.
-
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 02; 40(1):115-123.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|